PharmacyCodes



Rilutek en es it fr

Rilutek Brand names, Rilutek Analogs

Rilutek Brand Names Mixture

  • No information avaliable

Rilutek Chemical_Formula

C8H5F3N2OS

Rilutek RX_link

http://www.rxlist.com/cgi/generic3/riluzole.htm

Rilutek fda sheet

Rilutek msds (material safety sheet)

Rilutek Synthesis Reference

No information avaliable

Rilutek Molecular Weight

234.199 g/mol

Rilutek Melting Point

119 oC

Rilutek H2O Solubility

No information avaliable

Rilutek State

Solid

Rilutek LogP

2.784

Rilutek Dosage Forms

Tablet

Rilutek Indication

For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Rilutek Pharmacology

Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and/or time to tracheostomy. It is also neuroprotective in various in vivo experimental models of neuronal injury involving excitotoxic mechanisms. The etiology and pathogenesis of amyotrophic lateral sclerosis (ALS) are not known, although a number of hypotheses have been advanced. One hypothesis is that motor neurons, made vulnerable through either genetic predisposition or environmental factors, are injured by glutamate. In some cases of familial ALS the enzyme superoxide dismutase has been found to be defective.

Rilutek Absorption

Riluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.

Rilutek side effects and Toxicity

No information avaliable

Rilutek Patient Information

Patients should be advised to report any febrile illness to their physicians .

Patients and caregivers should be advised that RILUTEK should be taken on a regular basis and at the same time of the day (e.g., in the morning and evening) each day. If a dose is missed, take the next tablet as originally planned.

Patients should be warned about the potential for dizziness, vertigo, or somnolence and advised not to drive or operate machinery until they have gained sufficient experience on RILUTEK to gauge whether or not it affects their mental and/or motor performance adversely.

Whether alcohol increases the risk of serious hepatotoxicity with RILUTEK is unknown; therefore, patients being treated with RILUTEK should be discouraged from drinking excessive amounts of alcohol.

Patients should also be made aware that RILUTEK should be stored at temperatures between 20°-25°C (68°-77°F) and protected from bright light.

RILUTEK must be kept out of the reach of children.

Rilutek Organisms Affected

Humans and other mammals